Scarica l'app Stockscreener
23.02
1.96%
-0.46
Dopo l'orario di chiusura:
19.37
-3.65
-15.86%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Novo Nordisk shares rise as Hims abandons $49 weight-loss pill - Reuters
Hims & Hers shakes up weight-loss pricing, but investors stay wary - Global Cosmetics News
Hims & Hers Super Bowl Commercial 2026: Rich People Live Longer Because of Health Gap - Just Jared
Hims & Hers: GLP-1 Revenues Can't Be Relied On - Seeking Alpha
HIMS Bulls Vs. Bears: Can The Stock Recover After Pulling Its Compounded Weight-Loss Pill? - Stocktwits
Hims & Hers pulls copycat weight-loss pill - Yahoo Finance
Hims & Hers Suddenly Pulls Its $49 Wegovy Copycat After FDA Threatens Action - inc.com
HIMS Discontinues Compounded Semaglutide Pill Amid Stakeholder D - GuruFocus
Hims & Hers (HIMS) Stock Crashes as Company Pulls Plug on Wegovy Copy - MEXC
A $49 Ozempic Alternative Just Launched. Novo Nordisk Says It’s ‘Illegal’ and Dangerous - inc.com
Hims & Hers is promoting a new product to the massive NFL audience: a blood test designed to detect more than 50 types of cancer before symptoms show up. But the test’s reliability is questionable. - Facebook
Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - Benzinga
AI for investors - MLQ.ai
A $700 blood test promises to detect 50 different kinds of cancer. The results come with major caveats. - Business Insider
Hims to stop offering GLP-1 pill after FDA warned of crackdown - The Mighty 790 KFGO
Hims & Hers (HIMS) Shares Sink 16% as FDA Crackdown Halts Wegovy Copycat Pill - TipRanks
Hims Withdraws GLP-1 Weight Loss Pill After FDA Warning and Lawsuit Threats - AOL.com
Telehealth company scraps plans to sell cheap GLP-1 diet pill after FDA vows crackdown - New York Post
Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats - Fox Business
Hims & Hers halts sale of Wegovy copycat pill following FDA crackdown on weight-loss drugs - Mint
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash - BioPharma Dive
Hims & Hers removes a knock-off weight loss drug days after introducing it - Business Insider
Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill - Ottumwa Courier
HIMS Halts Compounded Weight-Loss Pill Amid Regulatory Pressure - GuruFocus
Hims & Hers Halts Sales of Wegovy Drug Amid FDA Pressure - intellectia.ai
Hims & Hers scraps copycat Wegovy weight-loss pill after probe - Fortune
Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny - Barron's
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI) - The Globe and Mail
Hims & Hers abandons copycat weight-loss drug in face of FDA probe - Financial Times
Hims & Hers Scraps Copycat Wegovy Weight-Loss Pill After Probe - Bloomberg.com
Key facts: Hims & Hers Health shares drop 14.1%; FDA restricts weight-loss pill - TradingView
Hims to stop offering copy of Wegovy pill following FDA scrutiny - Sherwood News
Hims & Hers to stop offering copies of Novo Nordisk's new Wegovy pill - marketscreener.com
Hims & Hers to Stop Offering Compounded Semaglutide Pill After FDA Crackdown - US News Money
Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown - marketscreener.com
Hims & Hers Health Inc says we have decided to stop offering access to compounded semaglutide pill - marketscreener.com
Hims & Hers Health Inc Says We Have Decided To Stop Offering Access To Compounded Semaglutide Pill - TradingView
Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version - The Wall Street Journal
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action - AOL.com
HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch - Stocktwits
Analysts Conflicted on These Healthcare Names: Cigna (CI), Hims & Hers Health (HIMS) and Omnicell (OMCL) - The Globe and Mail
Weight-loss drugs to dominate Super Bowl advertising - Reuters Connect
HIMS Stock Slumps After-Hours On FDA Crackdown, Regulatory Scrutiny Over Compounded Wegovy Pill Launch - Stocktwits
Hims & Hers Stock Pre-Market (-16%): FDA Crackdown on New Weight-Loss Pill - Trefis
Weight-loss drugs to compete on biggest stage with Super Bowl ads - Reuters
The healthcare companies advertising in Super Bowl LX - Modern Healthcare News
Hims & Hers Stock Pre-Market (-16%) : DOJ Probe & FDA Crackdown on Weight-Loss Drugs - Trefis
HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight - Law360
Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges. - Barron's
US signals crackdown on compounded weight-loss drugs; Hims shares tumble - Reuters
Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department - The Wall Street Journal
US announces crackdown on copycat weight-loss drugs - Financial Times
FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals (HIMS) - Bloomberg.com
FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs - The Wall Street Journal
HIMSS Health Faces DOJ Investigation for Potential Legal Violati - GuruFocus
HIMS Shares Decline 13% After Market Hours - GuruFocus
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):